ID
45568
Beschreibung
Principal Investigator: Elaine Mardis, PhD, The Genome Institute, Washington University School of Medicine, St. Louis, MO, USA MeSH: Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000661 This study aims to elucidate the genetic determinants of susceptibility to aggressive prostate carcinoma. To this end, germ line whole exome sequence has been generated from patients with aggressive prostate cancer. Whole genome sequence for a representative subset of tumors from patients whose cancer was resistant to primary therapy is included as well. This deep genomic interrogation will allow the identification of rare, functionally disruptive variants that may play a role in disease progession and response to treatment.
Link
Stichworte
Versionen (1)
- 23.01.23 23.01.23 - Dr. Christian Niklas
Rechteinhaber
Elaine Mardis, PhD, The Genome Institute, Washington University School of Medicine, St. Louis, MO, USA
Hochgeladen am
23. Januar 2023
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
dbGaP phs000661 Germline Sequencing for Aggressive Prostate Carcinoma
Subject ID, consent group, and affection status of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- StudyEvent: SEV1
- Subject ID, consent group, and affection status of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Subject ID, sample ID, and sample use variable of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Subject ID and race of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Sample ID, body site from which the tissue sample originated, tumor status of sample, and age of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
Ähnliche Modelle
Subject ID, consent group, and affection status of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- StudyEvent: SEV1
- Subject ID, consent group, and affection status of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Subject ID, sample ID, and sample use variable of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Subject ID and race of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
- Sample ID, body site from which the tissue sample originated, tumor status of sample, and age of participants with prostate cancer and involved in the "Germline Sequencing for Aggressive Prostate Carcinoma" project.
C4684638 (UMLS CUI [1,2])
C0441833 (UMLS CUI [1,2])